Persistence of HIV-1 Transmitted Drug Resistance Mutations

被引:87
作者
Castro, Hannah [1 ]
Pillay, Deenan [2 ]
Cane, Patricia [3 ]
Asboe, David [4 ]
Cambiano, Valentina [5 ]
Phillips, Andrew [5 ]
Dunn, David T. [1 ]
机构
[1] MRC, Clin Trials Unit, London WC2B 6NH, England
[2] UCL, Div Infect & Immun, London, England
[3] Publ Hlth England, Virus Reference Dept, London, England
[4] Chelsea & Westminster Hosp, Directorate HIV Med & Sexual Hlth, London, England
[5] UCL, Res Dept Infect & Populat Hlth, London, England
基金
欧盟第七框架计划; 英国医学研究理事会;
关键词
persistence; transmitted; HIV-1; resistance; mutations; IMMUNODEFICIENCY-VIRUS TYPE-1; VARIANTS; THERAPY; FITNESS; ABSENCE;
D O I
10.1093/infdis/jit345
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.
引用
收藏
页码:1459 / 1463
页数:5
相关论文
共 15 条
[1]   Persistence of primary drug resistance among recently HIV-1 infected adults [J].
Barbour, JD ;
Hecht, FA ;
Wrin, T ;
Liegler, TJ ;
Ramstead, CA ;
Busch, MP ;
Segal, MR ;
Petropoulos, CJ ;
Grant, RM .
AIDS, 2004, 18 (12) :1683-1689
[2]   Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update [J].
Bennett, Diane E. ;
Camacho, Ricardo J. ;
Otelea, Dan ;
Kuritzkes, Daniel R. ;
Fleury, Herve ;
Kiuchi, Mark ;
Heneine, Walid ;
Kantor, Rami ;
Jordan, Michael R. ;
Schapiro, Jonathan M. ;
Vandamme, Anne-Mieke ;
Sandstrom, Paul ;
Boucher, Charles A. B. ;
van de Vijver, David ;
Rhee, Soo-Yon ;
Liu, Tommy F. ;
Pillay, Deenan ;
Shafer, Robert W. .
PLOS ONE, 2009, 4 (03)
[3]  
Bezemer D, 2006, ANTIVIR THER, V11, P173
[4]  
Burns S, 2007, AIDS, V21, P1035, DOI 10.1097/QAD.0b013e3280b07761
[5]   The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions [J].
Cong, Mian-er ;
Heneine, Walid ;
Garcia-Lerma, J. Gerardo .
JOURNAL OF VIROLOGY, 2007, 81 (06) :3037-3041
[6]   Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes [J].
Jain, Vivek ;
Sucupira, Maria C. ;
Bacchetti, Peter ;
Hartogensis, Wendy ;
Diaz, Ricardo S. ;
Kallas, Esper G. ;
Janini, Luiz M. ;
Liegler, Teri ;
Pilcher, Christopher D. ;
Grant, Robert M. ;
Cortes, Rodrigo ;
Deeks, Steven G. ;
Hecht, Frederick M. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (08) :1174-1181
[7]   Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection [J].
Little, Susan J. ;
Frost, Simon D. W. ;
Wong, Joseph K. ;
Smith, Davey M. ;
Pond, Sergei L. Kosakovsky ;
Ignacio, Caroline C. ;
Parkin, Neil T. ;
Petropoulos, Christos J. ;
Richman, Douglas D. .
JOURNAL OF VIROLOGY, 2008, 82 (11) :5510-5518
[8]   Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1 [J].
Martinez-Picado, J ;
Savara, LV ;
Sutton, L ;
D'Aquila, RT .
JOURNAL OF VIROLOGY, 1999, 73 (05) :3744-3752
[9]   Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings [J].
Phillips, Andrew N. ;
Pillay, Deenan ;
Garnett, Geoff ;
Bennett, Diane ;
Vitoria, Marco ;
Cambiano, Valentina ;
Lundgren, Jens .
AIDS, 2011, 25 (06) :843-850
[10]   Evolutionary pathways of transmitted drug-resistant HIV-1 [J].
Pingen, Marieke ;
Nijhuis, Monique ;
de Bruijn, Johan A. ;
Boucher, Charles A. B. ;
Wensing, Annemarie M. J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (07) :1467-1480